Anaridex is used to treat advanced breast cancer in postmenopausal women.
- with intolerance to anastrozole, auxiliary components;
- during pregnancy, breastfeeding;
-Use during pregnancy and lactation
Anaridex applies inside. The recommended dose is 1 mg (one tablet) once a day.
In the early stages of invasive breast cancer (with positive hormone receptor values) in postmenopausal patients, the standard duration of adjuvant endocrine therapy is five years.
Patients with mild/moderate renal and liver dysfunction do not require dose adjustment.
In case of overdose, symptomatic, supportive therapy is carried out. It is necessary to careful monitoring of the patient. Dialysis is possible.
Digestive disorders: anorexia, nausea, diarrhea.
Neurological disorders: headache, carpal tunnel syndrome, drowsiness, sensitivity disorders.
Allergic reactions: manifestations of allergy (chills, chest pain, tremors, urticaria, skin rash), anaphylaxis, dermatitis.
Dermatological disorders: rash, thinning hair, alopecia, polymorphic erythema, skin vasculitis.
Musculoskeletal disorders: arthralgia, arthritis, impaired joint mobility, osteoporosis, bone pain, myalgia.
Genitourinary disorders: vaginal bleeding, vaginal dryness.